131.87 USD
-0.05 (-0.04%)
131.92 USD
+0.05 (+0.04%)
ChartMill assigns a Buy % Consensus number of 72% to ITCI. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 133.21. This target is 1.02% above the current price.
ITCI was analyzed by 18 analysts. The buy percentage consensus is at 72. So analysts seem to be have mildly positive about ITCI.
In the previous month the buy percentage consensus was at a similar level.
ITCI was analyzed by 18 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-04-02 | Cantor Fitzgerald | Reiterate | Neutral -> Neutral |
| 2025-02-24 | Mizuho | Downgrade | Outperform -> Neutral |
| 2025-02-21 | Needham | Reiterate | Hold -> Hold |
| 2025-01-31 | Canaccord Genuity | Downgrade | Buy -> Hold |
| 2025-01-22 | RBC Capital | Downgrade | Outperform -> Sector Perform |
| 2025-01-14 | Piper Sandler | Downgrade | Overweight -> Neutral |
| 2025-01-13 | Needham | Downgrade | Buy -> Hold |
| 2024-11-04 | JP Morgan | Maintains | Overweight -> Overweight |
| 2024-10-31 | Needham | Reiterate | Buy -> Buy |
| 2024-10-30 | Needham | Reiterate | Buy -> Buy |
| 2024-10-11 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2024-10-04 | RBC Capital | Maintains | Outperform -> Outperform |
| 2024-09-20 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-09-16 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-09-06 | Piper Sandler | Upgrade | Neutral -> Overweight |
| 2024-08-21 | JP Morgan | Maintains | Overweight -> Overweight |
| 2024-08-08 | Cantor Fitzgerald | Maintains | Overweight -> Overweight |
| 2024-08-08 | UBS | Maintains | Neutral -> Neutral |
| 2024-08-08 | Needham | Reiterate | Buy -> Buy |
| 2024-08-08 | RBC Capital | Maintains | Outperform -> Outperform |
| 2024-08-08 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2024-08-07 | Needham | Reiterate | Buy -> Buy |
| 2024-07-22 | Needham | Maintains | Buy -> Buy |
| 2024-06-25 | UBS | Downgrade | Buy -> Neutral |
| 2024-06-25 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2024-06-21 | Mizuho | Maintains | Buy -> Buy |
| 2024-06-20 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2024-06-18 | Needham | Maintains | Buy -> Buy |
| 2024-06-14 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-06-12 | JP Morgan | Maintains | Overweight -> Overweight |
INTRA-CELLULAR THERAPIES INC / ITCI FAQ
What do analysts expect the price target to be for INTRA-CELLULAR THERAPIES INC (ITCI)?
18 analysts have analysed ITCI and the average price target is 133.21 USD. This implies a price increase of 1.02% is expected in the next year compared to the current price of 131.87.
Can you provide the consensus rating for INTRA-CELLULAR THERAPIES INC stock?
The consensus rating for INTRA-CELLULAR THERAPIES INC (ITCI) is 72.2222 / 100 . This indicates that analysts generally have a positive outlook on the stock.
How many analysts have analysed INTRA-CELLULAR THERAPIES INC (ITCI)?
The number of analysts covering INTRA-CELLULAR THERAPIES INC (ITCI) is 18.